You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site

Continue

Go back

Go to Close Top

TWINRIX Safety Profile 1

TWINRIX adult safety and tolerability profile

TWINRIX was generally well tolerated

  • The assessment of safety and tolerability of TWINRIX was based on data from more than 6000 subjects who received the standard 3-dose schedule or rapid 4-dose schedule 1

Adverse reactions considered by the investigator as being at least possibly related to TWINRIX vaccination in adults 1

Adapted from the TWINRIX Product Monograph.

TWINRIX pediatric safety and tolerability profile

TWINRIX Junior was generally well tolerated

  • The assessment of safety and tolerability of TWINRIX Junior was based on data from ~800 subjects who received the standard 3-dose schedule 1

Adverse reactions considered by the investigator as being at least possibly related to TWINRIX Junior vaccination in children *1

Adapted from the TWINRIX Product Monograph.

* Following standard 3-dose schedule (0, 1, 6 months).
 Refers to adverse reactions observed in clinical trials with TWINRIX.

TWINRIX combined hepatitis A (inactivated) and hepatitis B (recombinant) vaccine is indicated for active immunization against hepatitis A and hepatitis B virus infection in adults, adolescents, children and infants. 1

TWINRIX will not protect against infection caused by other agents such as hepatitis C, hepatitis E and other pathogens known to infect the liver. It can be expected that hepatitis D will also be prevented by immunization with TWINRIX as hepatitis D (caused by the delta agent) does not occur in the absence of hepatitis B infection. 1

Reference:

  1. TWINRIX Product Monograph. November 30, 2018.

This page is for Healthcare Professionals only. If you are not a Healthcare Professional, please visit Twinrix.ca.